Latest Breaking News On - Generating new antibiotic incentives now - Page 2 : comparemela.com

Acurx Pharmaceuticals, Inc to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update

STATEN ISLAND, N.Y., April 23, 2024 /PRNewswire/ Acurx Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial.

Robertg shawahDavidp luciPrnewswire acurx pharmaceuticals incDrug administrationAcurx pharmaceuticalsAcurx pharmaceuticals incExchange commission on formChief executive officerChief financial officerGram positive selective spectrumQualified infectious disease productGenerating new antibiotic incentives nowLooking statementsPrivate securities litigation reform actExchange commission

Acurx Pharmaceuticals (ACXP) Granted FDA End of Phase 2 Meeting for Ibezapolstat for C difficile Infection

Acurx Pharmaceuticals (ACXP) Granted FDA End of Phase 2 Meeting for Ibezapolstat for C difficile Infection
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDavidp luciRobertj delucciaTrial oversight committeeAcurx pharmaceuticals incData monitoring committeeCompany scientific advisory boardEuropean medicines agency onDrug administrationAcurx pharmaceuticalsNew drug applicationMeeting requestMeeting packageBriefing documentEuropean medicines agencyScientific advice

Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development

As previously announced, planning is underway with FDA to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection As anticipated, an End of Phase 2.

United statesDavidp luciPrnewswire acurx pharmaceuticals incCompany scientific advisory boardAcurx pharmaceuticalsEuropean medicines agencyExchange commission on formSociety or healthcare epidemiology of americaDrug administrationData monitoring committeeInfectious diseases society of americaAcurx pharmaceuticals incTrial oversight committeeCompany phBriefing documentMedium sized enterprise

Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients

Ibezapolstat outperformed vancomycin showing eradication of fecal C. difficile at Day 3 of treatment in 15 of 16 treated patients (94%), versus vancomycin.

United statesUniversity of houstonDavidp luciKevin gareyRobertj delucciaAcurx pharmaceuticalsSociety or healthcare epidemiology of americaCompany phCompany scientific advisory boardExchange commissionData monitoring committeeUniversity of houston college pharmacyTrial oversight committeeEuropean medicines agencyDrug administrationExchange commission on form

Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure

All 15 ibezapolstat-treated patients in Phase 2b who achieved Clinical Cure at end of treatment remained free of C. difficile Infection recurrence through one month after EOT, for a Sustained.

United statesKevin gareyStuart johnsonRobertj delucciaDavidp luciAcurx pharmaceuticals incInfectious diseases society of americaUniversity of houston college pharmacyData monitoring committeeExchange commission on formDrug administrationCompany phTrial oversight committeeSociety or healthcare epidemiology of americaExchange commissionCompany scientific advisory board